S1P‐related modulators are being actively and extensively evaluated for the treatment of other diseases, but human‐based studies and cardiovascular disease‐targeting trials are still relatively few, and therefore, more data are needed to prove the availability of S1P‐based therapies, which may provide insights into its future use in cardiovascular diseases. This evidence concerns the gene MBTPS1 and cardiovascular disorder.